← Back to Calendar

Travere Therapeutics Q4 2025 Earnings

Travere Therapeutics · $TVTX

Standard Review Earnings

PDUFA Date

February 27, 2026

Time Remaining

25d ago

Review Type

Standard (10 mo)

Indication

Q4 2025 earnings + FILSPARI commercial + FSGS PDUFA update

Key Notes

Q4 2025 earnings reported ~February 27, 2026. Record Q4 FILSPARI demand: 908 new patient starts in IgAN. FY2025 revenue $490.73M (+110% YoY). FSGS sNDA PDUFA extended to April 13, 2026 after major amendment in January 2026.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar